Walleye Capital
ANIP icon

Walleye Capital’s ANI Pharmaceuticals ANIP Stock Holding History

Walleye Capital’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-3,400
Closed -$210K – 905
2019
Q4 		$210K Sell
3,400
-2,400
-41% -$159K 0.01% 1083
2019
Q3 		$423K Sell
5,800
-14,900
-72% -$1.11M 0.03% 837
2019
Q2 		$1.7M Sell
20,700
-14,100
-41% -$1M 0.19% 130
2019
Q1 		$2.46M Buy
+34,800
New +$2.05M 0.4% 16

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Walleye Capital's ANIP Position: Q1 2026 in Review

Walleye Capital increased its ANI Pharmaceuticals (ANIP) stake by 56% in Q1 2026, buying an estimated $5.13M and bringing the position to 183,075 shares worth $14.1M. The position accounts for 0.06% of the portfolio, ranked #286.

Walleye Capital first reported a position in ANIP in Q1 2019 and has held it in 13 quarters since. The position peaked at $19.8M in Q3 2025. 280 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

  • Walleye Capital held 183,075 shares of ANI Pharmaceuticals worth $14.1M as of Q1 2026.
  • Walleye Capital bought 65,768 ANI Pharmaceuticals shares in Q1 2026, an estimated $5.13M.
  • ANI Pharmaceuticals made up 0.06% of Walleye Capital's portfolio in Q1 2026, its #286 holding.
  • Walleye Capital first reported a position in ANI Pharmaceuticals in Q1 2019 and has held it in 13 quarters since.
  • Walleye Capital's ANI Pharmaceuticals position peaked at $19.8M in Q3 2025.
  • 280 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.